Tumor
microenvironment-specific magnetic resonance imaging (MRI)
contrast agents are conducive to accurate diagnoses by visualization
of biochemical and pathological changes for suitable treatment. Herein,
we reported a pH-responsive contrast agent DFeZd NP with MRI diagnosis
and tumor treatment capabilities. DFeZd NPs can map the pH change
by modulating the MR signal in different acid–base environments.
Moreover, T1 signals are stronger in the tumor site, which proves
efficient in distinguishing malignant tumors from normal tissues,
as well as demarcating the tumor boundary. Subsequently, sustained
supply of Fe through the Fe-based contrast agent leads to Fe redox
cycling and lipid peroxides, inducing ferroptosis in tumor cells.
Furthermore, under an acidic tumor microenvironment, in the presence
of ascorbic acid, increased Fe2+ is generated, which serves
as a stronger inducer of ferroptosis. Moreover, due to the different
relaxivity of Fe3+ and Fe2+, redox cycling and
ferroptosis in tumors can be monitored by MRI. Therefore, we propose
DFeZd NPs as accessible and promising Fe-based dopamine-derived contrast
agents for specific MRI imaging and ferroptosis induction for anticancer
therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.